Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Canbridge Pharmaceuticals's EV-to-OCF or its related term are showing as below:
FRA:MF1'
s EV-to-OCF Range Over the Past 10 Years
Min: -31.88 Med: -1.11 Max: 0.92
Current: -25.31
During the past 7 years, the highest EV-to-OCF of Canbridge Pharmaceuticals was 0.92. The lowest was -31.88. And the median was -1.11.
FRA:MF1's EV-to-OCF is ranked better than 84.7% of 1405
companies
in the Biotechnology industry
Industry Median: -3.4
vs FRA:MF1: -25.31
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Canbridge Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Canbridge Pharmaceuticals's share price for today is €0.188.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Canbridge Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Canbridge Pharmaceuticals EV-to-OCF Related Terms
Canbridge Pharmaceuticals EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Canbridge Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's EV-to-OCF falls into.
Canbridge Pharmaceuticals's current Enterprise Value is €117.08 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Canbridge Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-4.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canbridge Pharmaceuticals (FRA:MF1) has a EV-to-OCF of -25.29 as of Sep. 13, 2026. According to the industry distribution chart, Canbridge Pharmaceuticals ranks #215 out of 1405 companies in the Biotechnology industry, placing it in the top 15.3%.
Is Canbridge Pharmaceuticals' EV-to-OCF too high?
Canbridge Pharmaceuticals' current EV-to-OCF is -25.29. Based on the distribution chart, Canbridge Pharmaceuticals ranks #215 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Canbridge Pharmaceuticals has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Canbridge Pharmaceuticals' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Canbridge Pharmaceuticals ranks #215 out of 1405 companies for EV-to-OCF. This places Canbridge Pharmaceuticals in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Canbridge Pharmaceuticals's current EV-to-OCF is -25.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canbridge Pharmaceuticals stock overvalued right now?
Canbridge Pharmaceuticals (FRA:MF1) has a current EV-to-OCF of -25.29. The stock's GF Value™ is €0.04, compared to a current price of €0.19 — trading 370% above its estimated fair value. The current EV-to-OCF is -25.29. Canbridge Pharmaceuticals' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Canbridge Pharmaceuticals (FRA:MF1), the current EV-to-OCF is -25.29 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canbridge Pharmaceuticals (FRA:MF1) Overvalued in 2026?
Based on GuruFocus' analysis, Canbridge Pharmaceuticals stock appears to be overvalued.
The current stock price of €0.19 is trading 370% above its estimated GF Value™ of €0.04.
Key valuation signals for FRA:MF1:
EV-to-OCF: -25.29
GF Value™: €0.04 vs. price of €0.19 (370% above fair value)
No single metric tells the full story. See the FRA:MF1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canbridge Pharmaceuticals Inc is a biotechnology company engaged in the research, development, and commercialization of therapies targeting rare diseases. Its differentiated portfolio of therapeutics includes biologics, small molecules, and gene therapies, targeting prevalent rare disease indications that have unmet needs and market potential. The Group's portfolio is composed of approved products like Hunterase, Livmarli, and Gaurunning, and various assets currently in development like CAN106, CAN107, CAN104, and CAN105, all these targeting diseases such as Hunter syndrome and other lysosomal storage disorders, paroxysmal nocturnal hemoglobinuria, hemophilia A, metabolic disorders, rare cholestatic liver diseases, and neuromuscular diseases. The Group's main market is Mainland China.
48GF Score
Get the complete analysis for FRA:MF1
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:MF1 has been successfully added to your 
